Head to head
Mazdutide against Semaglutide
A GLP-1 and glucagon dual approved in China in 2025 against the GLP-1 agonist approved almost everywhere. Both are weekly injections sold for the same goal, and the regulatory gap is the fact most likely to matter to anyone reading from outside China.
Column A
MazdutideMazdutide (GLP-1 / glucagon dual agonist)
A GLP-1 and glucagon receptor dual agonist approved in China in 2025 for obesity and type 2 diabetes, the first of its class approved anywhere, and not approved by the FDA.
Column B
SemaglutideSemaglutide (GLP-1 receptor agonist)
A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
Side by side, on the facts we can check
| Attribute | Mazdutide | Semaglutide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Approved in China (2025) for obesity and type 2 diabetes; investigational elsewhere | FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management) |
| Half-life | ~5-7 days | ~7 days |
| Molecular weight | ~4,800 Da | 4,113.6 Da |
| Mechanism | Agonizes GLP-1 and glucagon receptors to reduce appetite and improve glucose control while increasing energy expenditure. | Activates the GLP-1 receptor, increasing insulin secretion when glucose is elevated, suppressing glucagon, slowing gastric emptying, and acting on hypothalamic appetite centers to reduce food intake. |
| Human studies cited | 2 | 5 |
| Legal status, US | Not approved | FDA-approved, prescription only |
Frequently asked questions
What is the difference between Mazdutide and Semaglutide?
Mazdutide: A GLP-1 and glucagon receptor dual agonist approved in China in 2025 for obesity and type 2 diabetes, the first of its class approved anywhere, and not approved by the FDA. Semaglutide: A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
Which has stronger research evidence, Mazdutide or Semaglutide?
This database does not grade compounds. It counts what was run in people: 2 of the 3 studies cited on the Mazdutide profile were human work, against 5 of 5 for Semaglutide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Mazdutide and Semaglutide FDA-approved?
Mazdutide: Approved in China (2025) for obesity and type 2 diabetes; investigational elsewhere. Semaglutide: FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management).
Related posts
Blog articles that cover Mazdutide or Semaglutide, newest first.
- Dispatch / Sep 12, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 8, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Longevity / Sep 8, 2026 / 12 minPeptides for Longevity: What the Evidence Actually Shows in 2026
- Metabolic / Sep 8, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.